Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis
Sponsor: Alexandria University
Summary
This study aims to assess the effect of finerenone on proteinuria and GFR progression in patients with non-diabetic glomerulonephritis.
Official title: Effect of Finerenone on Proteinuria and GFR Progression in Patients With Non Diabetic Glomerulonephritis: A Randomized Clinical Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-02-20
Completion Date
2025-09-10
Last Updated
2025-03-26
Healthy Volunteers
No
Conditions
Interventions
Finerenone
50 patients with biopsy proven glomerulonephritis who will receive 10 - 20 mg finerenone once daily orally in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 6 months.
Placebo
50 patients with biopsy proven glomerulonephritis who will receive placebo once daily in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 6 months.
Locations (1)
Faculty of Medicine, Aexandria University
Alexandria, Egypt